Take Home Regulation Page 4098

Page 4098

Federal Register

Vol. 66, No. 11 / Wednesday, January 17, 2001 / Rules and Regulations

(i) Unsupervised or “take-home” use.

To limit the potential for diversion of opioid agonist treatment medications to the illicit market, opioid agonist treatment medications dispensed to patients for unsupervised use shall be subject to the following requirements.

(1) Any patient in comprehensive maintenance treatment may receive a single take-home dose for a day that the clinic is closed for business, including Sundays and State and Federal holidays.

(2) Treatment program decisions on dispensing opioid treatment medications to patients for unsupervised use beyond that set forth in paragraph (i)(1) of this section, shall be determined by the medical director.

  1. Absence of recent abuse of drugs (opioid or nonnarcotic),

    including alcohol;

  2. Regularity of clinic attendance;
  3. Absence of serious behavioral problems at the clinic;
  4. Absence of known recent criminal activity, e.g., drug dealing;
  5. Stability of the patient’s home environment and social relationships;
  6. Length of time in comprehensive maintenance treatment;
  7. Assurance that take-home medication can be safely stored within the patient’s home; and
  8. Whether the rehabilitative benefit the patient derived from decreasing the frequency of clinic attendance outweighs the potential risks of diversion.

(3) Such determinations and the basis for such determinations consistent with the criteria outlined in paragraph (i)(2) of this section shall be documented in the patient’s medical record. If it is determined that a patient is responsible in handling opioid drugs, the following restrictions apply:

  1. During the first 90 days of treatment, the take-home Supply (beyond that of paragraph (i)(1) of this section) is limited to a single dose each week and the patient shall ingest all other doses under appropriate supervision as provided for under the regulations in this subpart.
  2. In the second 90 days of treatment, the take-home Supply (beyond that of paragraph (i)(1) of this section) is two doses per week.
  3. In the third 90 days of treatment, the take-home supply (beyond that of paragraph (i)(1) of this section) is three doses per week.
  4. In the remaining months of the first year, a patient may be given a maximum 6-day supply of take-home medication.
  5. After 1 year of continuous treatment, a patient may be given a maximum 2-week supply of take-home medication.
  6. After 2 years of continuous treatment, a patient may be given a maximum one-month supply of take-home medication, but must make monthly visits.

(4) No medications shall be dispensed to patients in short-term detoxification treatment or interim maintenance treatment for unsupervised or take-home use.

Similar Posts

  • Presidential Notes

    Admin 03/17/2022

    Stan Novick Stigma (STIG-ma): noun {From the Latin for “mark” or “brand”} a scar left by a hot iron a mark of shame or discredit an identifying mark or characteristic, i.e.: a specific diagnostic sign of a disease Everyone touched positively by methadone maintenance treatment is familiar with stigmatization. Patients, family members, friends, staff- we…

  • Reception

    Admin 08/15/2021

    Welcome to The President’s Office and to the National Alliance for Medication Assisted Recovery or NAMA Recovery. NAMA Recovery has gone through some significant changes in the past few years. We are proud of the MARS Project the first project of its kind that provides recovery services to patients receiving Medication Assisted Treatment (MAT). As…

  • Stigma: The Invisible Barrier by Herman Joseph, Ph.D. and Joycelyn Woods, M.A.

    Admin 03/28/2021

    Herman Joseph, Ph.D. is a member of NAMA’s Advisory Board and has been involved in methadone treatment and research since it’s beginning. This article is excerpted from Dr. Joseph’s dissertation on stigma. Joycelyn Woods, M.A. is Vice President of NAMA and has a graduate dreree in neuroscience and has worked in the field for twenty-five…

  • Make a Donation

    Admin 11/13/2022

    NAMA receives no funding for our advocacy work or to maintain our websites. Won’t you please consider making a donation? Making a Donation by Personal Check Checks or Money Orders should be made out to the: National Alliance of Methadone Advocates Mail it to: National Alliance of Methadone Advocates 435 Second Avenue New York, NY…

  • Workshop Wednesday, October 10th

    Admin 11/25/2021

    Workshop Wednesday, October 10th Past Present and Future: A Selection of Unfinished Business in Methadone Treatment Moderator, Howard Lotsof, NAMA Acting Membership Director Gary Nessenbaum, Washington Advocates for Methadone Maintenance (President). The Patients’ Perspectives on the Changes in the Methadone Treatment System. Carmen Pearman, NAMA Regional Director and The MAG of Indiana (President). Tapering –…

  • Stop Methadone Ignorance

    Admin 05/22/2021

    STOP METHADONE IGNORANCE It is not uncommon for individuals with a long history of illicit opiate use to remain in methadone treatment as a long term patient. Many often say that without methadone treatment they would probably be dead. Other forms of treatment were not effective and they had come to believe that they would…